论文部分内容阅读
该课题研究的目的是,探讨高剂量的β受体激动剂治疗哮喘可能发生的副作用,及其与糖皮质激素联合应用可能产生的不良相互影响。 方法 选择34例(完成试验28例)16～64岁轻、中度哮喘患者,至少一年内未发作,过敏体质.PD_(20)<8μmol/L,若吸入激素应<12μmol/L,给予4.5％高渗盐吸入可诱导出痰液,除短效β受体激动剂及合用经鼻吸入的糖皮质激素治疗外,停用其它哮喘用药。实验分4组:T组(Terbutaline)特普他林500μg qid;B组(Budesonide)布地奈德500μg Bid;C组(Combined treatment)特普他林500μg qid,布地奈德400μgBid,P组(Placebo)安慰剂。在每疗程(6周)末进行高渗盐激发试验/痰诱导试验。3～7天后做乙酰甲胆碱激发试验。
The aim of this study was to investigate the possible side effects of high-dose beta-agonists in the treatment of asthma and their potential adverse effects on the combination with glucocorticoids. Methods: 34 patients (28 completed) were given mild to moderate asthma aged 16-64 years with at least one year without any episode of allergic disease. PD_ (20) <8μmol / L, if the inhaled hormone should be <12μmol / L, % Hypertonic saline inhalation can induce sputum, in addition to short-acting beta-agonists and combined nasal inhalation of glucocorticoid treatment, disable other asthma medication. The experiment was divided into four groups: terbutaline 500μg qid; Budesonide budesonide 500μg Bid; group C combined treatment with terbutaline 500μg qid, budesonide 400μg Bid, group P (Placebo Placebo. The hypertonic salt challenge test / sputum induction test was performed at the end of each course (6 weeks). 3 to 7 days after methacholine challenge test.